Clinical Trial Update: Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating pasireotide for reactive hypoglycemia after gastric bypass (post-bariatric hypoglycemia).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-bariatric Hypoglycemia
• Reactive Hypoglycemia

Drugs mentioned

• SIGNIFOR (PASIREOTIDE)

Snippet

Sponsor: Zealand University Hospital | Conditions: Hypoglycemia, Reactive | Phase 4 | Status: UNKNOWN